The DEA Wants Five More Tryptamines in Schedule I. Comments Close October 23
A proposed rule would place five tryptamines into Schedule I. It is the second attempt at the same action, and comments close October 23.
Read More
An MDMA Course Takes 34 Clinician Hours Per Patient
Israeli MDMA trials run 15 sessions over three to four months, including an eight hour dosing day with two therapists present. The staffing math is the part US clinics should be reading.
Read More
Whether the Ketamine Experience Matters Depends on Which Questionnaire You Use
A new letter in npj Mental Health Research argues a 2024 meta-analysis compared ketamine and psilocybin with different instruments. Across the same ketamine studies, one scale explains 3 percent of outcomes and another explains 15 percent.
Read More
Dissociation Was Tied to Better Esketamine Outcomes in a Small Study
Higher dissociation scores went with better depression outcomes on subcutaneous esketamine, with derealization driving the difference. The study was small, open label and exploratory.
Read More
6 Regulatory Deadlines Ketamine Clinics Should Have on the Calendar
From FDA's October 5 psychedelics docket to the DEA telehealth expiration and Medicare's 2027 in-person rule, six dates every ketamine clinic should plan around.
Read More
Two Ketamine Brain Studies Point to the Same Moment: The Day After the Infusion
Oxford found ketamine quieted the habenula 24 hours after infusion. A Texas A&M analysis linked 24-hour brain changes in older veterans to day-7 improvement.
Read More
Definium’s LSD Tablet Clears a Third Phase 3, With a Design Aimed at the Blinding Problem
Definium's DT120 met its primary endpoint in the Panorama trial. A low-dose arm was added to address functional unblinding, and a dose-response pattern emerged.
Read More
FDA’s Psychedelics Hearing Was Really a Fight Over the Label
FDA heard four hours of testimony on psychedelic approval and asked no questions. The real contest was over label language, which decides who can deliver these drugs.
Read More
Medicaid Is the Largest Behavioral Health Payer. A New Report Asks What Happens Next
A Center for Health Care Strategies report examines how psychedelic-assisted therapy could reach Medicaid. Some states already cover off-label IV ketamine.
Read More
The Only Two Placebo-Controlled Microdosing Trials Found Nothing
A systematic review screened 897 references on psilocybin microdosing. Of 11 studies, only two were placebo controlled, and neither found a benefit.
Read More